Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $139.7100 (0.31%) ($138.1900 - $142.0000) on Wed. Oct. 3, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 1.77% (three month average) | RSI | 34 | Latest Price | $139.7100(0.31%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE declines -2.5% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(50%) XBI(47%) IWO(46%) IWC(43%) IWM(42%) | Factors Impacting SAGE price | SAGE will decline at least -0.885% in a week (0% probabilities). UUP(-12%) VXX(-11%) VIXM(-11%) TLT(-7%) SHY(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -0.885% (StdDev 1.77%) | Hourly BBV | 0 () | Intraday Trend | 0.1% | | | |
|
1 - 5 Day Possible Target | $132.53(-5.14%) | Resistance Level | $145.93 | 5 Day Moving Average | $139.45(0.19%) | 10 Day Moving Average | $141.04(-0.94%) | 20 Day Moving Average | $145.93(-4.26%) | To recent high | -17.4% | To recent low | 1.2% | Market Cap | $7.256b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |